Fulcrum Therapeutics (FULC) Common Equity (2019 - 2025)
Historic Common Equity for Fulcrum Therapeutics (FULC) over the last 7 years, with Q3 2025 value amounting to $198.4 million.
- Fulcrum Therapeutics' Common Equity fell 2290.21% to $198.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $198.4 million, marking a year-over-year decrease of 2290.21%. This contributed to the annual value of $243.0 million for FY2024, which is 333.39% up from last year.
- Per Fulcrum Therapeutics' latest filing, its Common Equity stood at $198.4 million for Q3 2025, which was down 2290.21% from $214.4 million recorded in Q2 2025.
- Fulcrum Therapeutics' Common Equity's 5-year high stood at $296.3 million during Q1 2023, with a 5-year trough of $110.9 million in Q2 2021.
- Over the past 5 years, Fulcrum Therapeutics' median Common Equity value was $221.4 million (recorded in 2022), while the average stood at $218.0 million.
- As far as peak fluctuations go, Fulcrum Therapeutics' Common Equity soared by 12224.92% in 2021, and later crashed by 2790.29% in 2024.
- Quarter analysis of 5 years shows Fulcrum Therapeutics' Common Equity stood at $211.5 million in 2021, then dropped by 5.95% to $198.9 million in 2022, then increased by 18.22% to $235.2 million in 2023, then rose by 3.33% to $243.0 million in 2024, then decreased by 18.38% to $198.4 million in 2025.
- Its Common Equity stands at $198.4 million for Q3 2025, versus $214.4 million for Q2 2025 and $228.5 million for Q1 2025.